Literature DB >> 16843481

Non-specific binding to protein A Sepharose and protein G Sepharose in insulin autoantibody assays may be reduced by pre-treatment with glycine or ethanolamine.

Alistair J K Williams1, Alastair J Norcross, Kyla A Chandler, Polly J Bingley.   

Abstract

Insulin autoantibody (IAA) microassays are widely used for predicting type 1 diabetes. As levels of IAA are often low in type 1 diabetes, non-specific binding (NSB) needs to be minimised if assays are to achieve high analytical sensitivity. IAA microassays use protein A Sepharose (PAS) or protein G Sepharose (PGS) to isolate the antibody-bound label, but NSB by the gel can differ between commercially-produced batches. We investigated whether pre-incubation of gel with glycine or ethanolamine could overcome this problem. Batches of PAS/PGS shown to have high NSB (0.3-3.2%) were incubated with glycine or ethanolamine at various pHs between 8 and 10.6 for 2-18 h at 4 degrees C or room temperature. Treating PAS at pH 10.6 with 0.2 M glycine overnight at room temperature reduced NSB by >84%, with minimal reduction in specific binding (<5%). Treating PGS at pH 10.6 with 0.2 M ethanolamine overnight at 4 degrees C reduced background by >95%, with minimal reduction in specific binding by most sera. Treatment at high pH was critical in reducing NSB to both PAS and PGS, with slight reduction at pH 8, but a major reduction at pH 10.6. Pre-treatment with glycine or ethanolamine allows "poor" batches of PAS or PGS to be used in sensitive IAA assays, improving both consistency and performance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16843481     DOI: 10.1016/j.jim.2006.06.003

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation.

Authors:  Rhian M Evans; Haitao You; Shahid Hameed; Christophe Altier; Alexandre Mezghrani; Emmanuel Bourinet; Gerald W Zamponi
Journal:  J Biol Chem       Date:  2009-11-03       Impact factor: 5.157

2.  'Insulin autoantibody affinity measurement using a single concentration of unlabelled insulin competitor discriminates risk in relatives of patients with type 1 diabetes.

Authors:  R M Curnock; C R Reed; S Rokni; J W Broadhurst; P J Bingley; A J K Williams
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

3.  COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain.

Authors:  Massimiliano Secchi; Elena Bazzigaluppi; Cristina Brigatti; Ilaria Marzinotto; Cristina Tresoldi; Patrizia Rovere-Querini; Andrea Poli; Antonella Castagna; Gabriella Scarlatti; Alberto Zangrillo; Fabio Ciceri; Lorenzo Piemonti; Vito Lampasona
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

4.  Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.

Authors:  Simke Demeester; Bart Keymeulen; Leonard Kaufman; Annelien Van Dalem; Eric V Balti; Ursule Van de Velde; Patrick Goubert; Katrijn Verhaeghen; Howard W Davidson; Janet M Wenzlau; Ilse Weets; Daniel G Pipeleers; Frans K Gorus
Journal:  Diabetes Care       Date:  2015-01-12       Impact factor: 19.112

5.  Requirement of a Blocking Step in Affinity Purification of Polyclonal Antibodies.

Authors:  Sepideh Hamzehlou; Paul R Albert; Mohammad M Farajollahi
Journal:  Int J Mol Cell Med       Date:  2015

6.  A/H1N1 hemagglutinin antibodies show comparable affinity in vaccine-related Narcolepsy type 1 and control and are unlikely to contribute to pathogenesis.

Authors:  Alexander Lind; Ilaria Marzinotto; Cristina Brigatti; Anita Ramelius; Lorenzo Piemonti; Vito Lampasona
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

7.  Elevations in blood glucose before and after the appearance of islet autoantibodies in children.

Authors:  Katharina Warncke; Andreas Weiss; Peter Achenbach; Thekla von dem Berge; Reinhard Berner; Kristina Casteels; Lidia Groele; Konstantinos Hatzikotoulas; Angela Hommel; Olga Kordonouri; Helena Elding Larsson; Markus Lundgren; Benjamin A Marcus; Matthew D Snape; Agnieszka Szypowska; John A Todd; Ezio Bonifacio; Anette-G Ziegler
Journal:  J Clin Invest       Date:  2022-10-17       Impact factor: 19.456

8.  Young infants exhibit robust functional antibody responses and restrained IFN-γ production to SARS-CoV-2.

Authors:  Anu Goenka; Alice Halliday; Michaela Gregorova; Emily Milodowski; Amy Thomas; Maia Kavanagh Williamson; Holly Baum; Elizabeth Oliver; Anna E Long; Lea Knezevic; Alistair J K Williams; Vito Lampasona; Lorenzo Piemonti; Kapil Gupta; Natalie Di Bartolo; Imre Berger; Ashley M Toye; Barry Vipond; Peter Muir; Jolanta Bernatoniene; Mick Bailey; Kathleen M Gillespie; Andrew D Davidson; Linda Wooldridge; Laura Rivino; Adam Finn
Journal:  Cell Rep Med       Date:  2021-06-09

9.  Assessment and Management of Anti-Insulin Autoantibodies in Varying Presentations of Insulin Autoimmune Syndrome.

Authors:  David Church; Luís Cardoso; Richard G Kay; Claire L Williams; Bernard Freudenthal; Catriona Clarke; Julie Harris; Myuri Moorthy; Efthmia Karra; Fiona M Gribble; Frank Reimann; Keith Burling; Alistair J K Williams; Alia Munir; T Hugh Jones; Dagmar Führer; Lars C Moeller; Mark Cohen; Bernard Khoo; David Halsall; Robert K Semple
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

10.  Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study.

Authors:  Vito Lampasona; Massimiliano Secchi; Marina Scavini; Elena Bazzigaluppi; Cristina Brigatti; Ilaria Marzinotto; Alberto Davalli; Amelia Caretto; Andrea Laurenzi; Sabina Martinenghi; Chiara Molinari; Giordano Vitali; Luigi Di Filippo; Alessia Mercalli; Raffaella Melzi; Cristina Tresoldi; Patrizia Rovere-Querini; Giovanni Landoni; Fabio Ciceri; Emanuele Bosi; Lorenzo Piemonti
Journal:  Diabetologia       Date:  2020-10-08       Impact factor: 10.122

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.